Growth Factors
CJC-1295
GHRH analog
CJC-1295 (GHRH analogue, modified GRF 1-29)
Research context
CJC-1295 is a modified GRF(1-29) sequence carrying four amino acid substitutions that confer resistance to DPP-4 cleavage and increase plasma stability relative to the native fragment. Research examines GHRH receptor binding and growth hormone secretion in pituitary cell preparations.
Common assays: GHRH receptor binding · Pituitary cell GH secretion · DPP-4 resistance characterisation
Specification
| Designation | GHRH analog |
|---|---|
| Full name | CJC-1295 (GHRH analogue, modified GRF 1-29) |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg |
| CAS number | 863288-34-0 |
| Molecular formula | C152H252N44O42 |
| Molecular weight | 3367.90 g/mol |
| Formats | 15 mL Nasal Spray · 15 mL Oral Spray |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C. |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Teichman SL, Neale A, Lawrence B, et al.Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormoneJournal of Clinical Endocrinology & Metabolism · 2006 Find on PubMed ↗
Common questions
What is the difference between CJC-1295 with and without DAC?
The DAC (drug affinity complex) version carries a maleimide group that binds serum albumin, substantially extending half-life. The version without DAC is the tetrasubstituted GRF(1-29) sequence alone.
Which four substitutions define CJC-1295?
D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27 — each reported to reduce enzymatic degradation in the published characterisation.
Same pathway
Related compounds
CJC-1295 / Ipamorelin
GH Blend
A prepared blend pairing a GHRH analogue with a selective ghrelin receptor secretagogue.
Tesamorelin
GHRH analog
A stabilised 44-residue GHRH analogue carrying an N-terminal hexenoyl modification.
IGF-1 LR3
Insulin-like growth factor-1 LR3
An 83-residue IGF-1 analogue engineered for reduced binding-protein affinity.